Want to see DRUG full AI Analyst Report?
Top Page
Bright Minds Biosciences
(NASDAQ:DRUG)
Select Model
Select Model
Rating:55Neutral
Price Target:
$69.00
▼(-13.20% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily held back by weak financial performance: no revenue, widening losses, and accelerating cash burn. A strong, low-debt balance sheet improves funding flexibility, while technicals are moderately positive (price above key moving averages with constructive momentum). Valuation remains challenged due to ongoing losses and no dividend support.
Positive Factors
Low leverage
Extremely low debt reduces refinancing pressure and limits interest-related demands on a pre-commercial business. This gives Bright Minds greater financial flexibility to direct available capital toward clinical development and pursue funding or partnering decisions from a stronger balance-sheet position.
Negative Factors
No commercial revenue
Without product revenue, Bright Minds cannot currently fund operations through a recurring commercial business. Its financial outlook therefore remains dependent on successful development, future partnerships, or additional capital, increasing exposure to clinical execution and financing outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Extremely low debt reduces refinancing pressure and limits interest-related demands on a pre-commercial business. This gives Bright Minds greater financial flexibility to direct available capital toward clinical development and pursue funding or partnering decisions from a stronger balance-sheet position.
Read all positive factors
Bright Minds Biosciences (DRUG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$642.74M
Dividend YieldN/A
Average Volume (3M)149.22K
Price to Earnings (P/E)―
Beta (1Y)5.62
Revenue GrowthN/A
EPS Growth-120.28%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.76
Shares Outstanding9,864,061
10 Day Avg. Volume91,664
30 Day Avg. Volume149,218
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.08
Price to Sales (P/S)0.00
P/FCF Ratio-66.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$145.00Price Target Upside82.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.52
Revenue Forecast (FY)N/A
Bright Minds Biosciences Business Overview & Revenue Model
Company Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for ep...
How the Company Makes Money
Bright Minds Biosciences does not appear to have a mature, recurring commercial product revenue base because it is a clinical-stage drug developer. As a result, its ability to generate revenue and fund operations is typically driven by (a) capital...
Bright Minds Biosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -40.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -33.94M | -12.15M | -2.73M | -7.30M | -14.96M | -27.64K |
| Net Income | -24.75M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
Balance Sheet | ||||||
| Total Assets | 310.84M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 308.33M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total Debt | 65.70K | 125.78K | 118.96K | 73.55K | 139.91K | 0.00 |
| Total Liabilities | 2.55M | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K |
| Stockholders Equity | 308.30M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
Cash Flow | ||||||
| Free Cash Flow | -25.00M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Operating Cash Flow | -25.00M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 277.00M | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M |
Bright Minds Biosciences Technical Analysis
Negative
79.49
Price Trends
74.47
Negative
76.65
Negative
77.86
Negative
Market Momentum
-1.95
Positive
31.78
Neutral
6.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRUG, the sentiment is Negative. The current price of 79.49 is above the 20-day moving average (MA) of 76.32, above the 50-day MA of 74.47, and above the 200-day MA of 77.86, indicating a bearish trend. The MACD of -1.95 indicates Positive momentum. The RSI at 31.78 is Neutral, neither overbought nor oversold. The STOCH value of 6.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DRUG.
Bright Minds Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
DRUG
Bright Minds Biosciences
66.91
24.74
58.67%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.21
-3.79
-94.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.